Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $1.89 per share and revenue of $191.2480 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%.The business had revenue of $135.55 million during the quarter. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Trading Up 0.3%

Shares of Collegium Pharmaceutical stock opened at $36.10 on Tuesday. The business has a fifty day simple moving average of $35.70 and a two-hundred day simple moving average of $32.51. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $39.95. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 34.71 and a beta of 0.61. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10.

Collegium Pharmaceutical announced that its Board of Directors has initiated a stock repurchase plan on Monday, July 7th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the specialty pharmaceutical company to buy up to 15.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

COLL has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Wednesday, October 8th. HC Wainwright upgraded Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price objective on the stock in a research report on Monday, August 11th. Needham & Company LLC reiterated a “buy” rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.33.

Insider Buying and Selling

In related news, Director Gino Santini sold 5,405 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $37.19, for a total value of $201,011.95. Following the transaction, the director owned 95,042 shares in the company, valued at approximately $3,534,611.98. This trade represents a 5.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Scott Dreyer sold 16,389 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $38.21, for a total value of $626,223.69. Following the completion of the transaction, the executive vice president owned 103,613 shares in the company, valued at $3,959,052.73. The trade was a 13.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 55,792 shares of company stock worth $2,084,207 over the last three months. Company insiders own 2.51% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC increased its position in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after purchasing an additional 4,625 shares during the period. Jane Street Group LLC grew its position in Collegium Pharmaceutical by 218.7% in the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Collegium Pharmaceutical by 3.7% during the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after acquiring an additional 2,592 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.